Pesarrodona M, Jauset T, Diaz-Riascos ZV, Sanchez-Chardi A, Beaulieu ME, Seras-Franzoso J, Sanchez-Garcia L, Balta-Foix R, Mancilla S, Fernandez Y, Rinas U, Schwartz S Jr, Soucek L, Villaverde A, Abasolo I, Vazquez E

Advanced Science (Weinh). 2019 Jul 24;6(18):1900849. doi: 10.1002/advs.201900849. eCollection 2019 Sep 18.


Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44‐targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.